RNA-seq of combinatory treatment of gemcitabine+UVI5008 and gemcitabine+MS275 in human pancreatic adenocarcinoma human cell lines
RNA-seq of combinatory treatment of gemcitabine+UVI5008 and gemcitabine+MS275 in human pancreatic adenocarcinoma human cell lines
BxPC-3 cells were treated with either 1 μM gemcitabine (Gem), MS275 (5 μM), MS275 (1 μM) + Gem (0.01 μM) or left untreated for 48 hours. MIA PaCa-2 cells were treated with either Gem (1 μM), MS275 (10 μM), UVI5008 (1 μM), MS275 (5 μM) + Gem (0.5 μM), UVI5008 (0.5 μM) + Gem (1 μM) or left untreated for 48 hours. RNA was extracted using PureLink™ RNA Mini Kit (Invitrogen, MA, USA), according to the manufacturer's instructions. RNA quality was assessed using Agilent 2100 Bioanalyzer and the Agilent RNA 600 Nano Kit (Agilent Technologies, CA, USA). Samples with RIN value and concentration above 8 and 100 ng/μL, respectively were selected. Library was prepared using Illumina TruSeq stranded mRNA kit.